Εξειδίκευση τύπου :	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	A phase II study on the use of convalescent plasma for the treatment of severe COVID-19- A propensity score-matched control analysis
Δημιουργός/Συγγραφέας:	Pappa, Vasiliki Bouchla, Anthi Terpos, Evangelos Thomopoulos, Thomas P Rosati, Margherita [EL] Στέλλας, Δημήτρης[EN] Stellas, Dimitris Antoniadou, Anastasia Mentis, Andreas Papageorgiou, Sotirios G Politou, Marianna Kotanidou, Anastasia Kalomenidis, Ioannis Poulakou, Garyfalia Jahaj, Edison Korompoki, Eleni Grigoropoulou, Sotiria Hu, Xintao Bear, Jenifer Karaliota, Sevasti Burns, Robert Pagoni, Maria Trontzas, Ioannis Grouzi, Elisavet Labropoulou, Stavroula Stamoulis, Kostantinos Bamias, Aristotelis Tsiodras, Sotirios Felber, Barbara K Pavlakis, George N Dimopoulos, Meletios- Athanasios
Εκδότης:	MDPI
Ημερομηνία:	2021-04-11
Γλώσσα:	Αγγλικά
ISSN:	2076-2607
DOI:	10.3390/microorganisms9040806
Άλλο:	33920489
Περίληψη:	COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from symptom onset. During a median follow-up of 28.5 days, 56/60 patients fully recovered and 1 patient remained in the ICU. The death rate in the CP group was 3.4% vs. 13.6% in the control group. By multivariate analysis, CP recipients demonstrated a significantly reduced risk of death [HR: 0.04 (95% CI: 0.004-0.36), p: 0.005], significantly better overall survival by Kaplan-Meir analysis (p < 0.001), and increased probability of extubation [OR: 30.3 (95% CI: 2.64-348.9), p: 0.006]. Higher levels of antibodies in the CP were independently associated with significantly reduced risk of death. CP infusion was safe with only one grade 3 adverse event (AE), which easily resolved. CP used early may be a safe and effective treatment for patients with severe COVID-19 (trial number NCT04408209).
Τίτλος πηγής δημοσίευσης:	Microorganisms Special Issue: COVID-19: Focusing on Epidemiologic, Virologic, and Clinical Studies
Τόμος/Κεφάλαιο:	9
Τεύχος:	4
Σελίδες:	806
Θεματική Κατηγορία:	[EL] Παθολογία[EN] Pathology [EL] Βιοχημεία[EN] Biochemistry [EL] Ανοσολογία[EN] Immunology [EL] Μικροβιολογία[EN] Microbiology [EL] Ιατρική[EN] Medicine
Λέξεις-Κλειδιά:	COVID-19 SARS-CoV-2 antibodies Convalescent plasma Efficacy
Κάτοχος πνευματικών δικαιωμάτων:	Copyright © 2021 by the Authors. Licensee MDPI, Basel, Switzerland
Ηλεκτρονική διεύθυνση στον εκδότη (link):	https://www.mdpi.com/2076-2607/9/4/806
Ηλεκτρονική διεύθυνση περιοδικού (link) :	https://www.mdpi.com/journal/microorganisms
Εμφανίζεται στις συλλογές:	Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο